fda glp-1 compounding enforcement november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA is short-sighted on compounding

with vitamin C and selenium

Additional benefits of GLP-1 include the reduction of risk for adverse cardiovascular events in individuals with obesity and or Type 2 Diabetes due to its anti-inflammatory action

First, titles and abstracts were screened to exclude irrelevant articles, conference abstracts without full text, and non-English publications

Pure GIP agonists, when tested without GLP-1 agonism, havent shown impressive weight loss results in early studies

Health authorities discourage the use of BPC-157 due to insufficient human safety data, and it is not approved by any drug regulatory agency for human use